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Taking advantage of BRET, a mutant firefly luciferase with higher pH- and thermo-stability than the 5 
wild-type could be coupled with the red-emitting fluorescent protein of mCherry in both a fused and 
unfused format. The BRET pair allows >40% of the light emitted to be red shifted over 600nm to the 
mCherry acceptor wavelength. Taking the expected quantum yield for mCherry (0.22), a good fit to 
predicted light transfer is shown, with no other losses. Two measurements are considered for ATP 
determination: a) a ratiometric technique for ATP measurement using both donor and acceptor emission 10 
intensities, making the calibration slope independent of protein concentration in a broad range. This 
measurement was limited by the BRET efficiency and the low quantum yield of the mCherry acceptor, 
but this detection limit might be improved with other fluorescent proteins with higher quantum yield. The 
fused BRET pair also resulted in a small increase in the BRET ratio. b) an ATP dependent shift in the 
wavelength maximum using just the acceptor mCherry emission was also proposed for ATP 15 
determination. This did not require a high BRET efficieny and only uses emisson above 600nm to obtain 
the acceptor emission maximum, but not its intensity; it is independent of protein concentration across a 
broad range. This offers a novel and robust method for determination of ATP between 10-11 - 10-5 M with 
an easy baseline calibration with ATP concentration >10-4 M. 
Introduction 20 
ATP, as the universal energy source for cellular function, is 
present in every type of biological cell and plays a critical role in 
energy exchange1. Therefore ATP measurement is crucial in 
analysis of cellular mechanisms, enzymatic processes and 
biosynthesis2. Furthermore, since all living organisms contain 25 
ATP, it finds widespread application in diagnostic assays of 
toxicity and contamination by microorganisms in varied fields 
such as the pharmaceutical industry, blood banks, food and water 
processing and environmental pollution3.  
 Among the simplest methods for ATP measurement are 30 
chromogenic and colorimetric techniques in which a result can 
often be read by eye1,4,5. However, probably the most promising 
and most studied approach to ATP measurement has been 
enzyme-linked. Since ATP is critical in numerous enzyme 
pathways, there are many possibilities to exploit assays designed 35 
for a selective enzyme substrate, formatted so they are limited by 
the ATP concentration, rather than the primary substrate 
concentration. In this context, due to its high sensitivity and 
selectivity, the bioluminescent firefly luciferase (Fluc) -based 
assay still remains the most widely used technique to measure 40 
ATP6. The firefly luciferase enzyme reaction has a fast response 
(milliseconds) and a broad range for ATP detection. Other 
adenosine-containing nucleotides such as AMP or adenosine 
diphosphate (ADP) do not react with the enzyme, so the reaction 
is highly specific to ATP. Theoretically sensitivity is extremely 45 
high, because there should be no background signal in the 
absence of ATP2. Nevertheless, ATP measured down to the 
attomole level still requires low noise instrumentation7,8 to 
resolve the signal2 with any background signal due to extraneous 
light eliminated9.  50 
 Another problem encountered in complex media and tissues 
which absorb a large proportion of the light below 600 nm, is the 
short wavelength of emission for the luciferase-luciferin (Fluc-
LH2) system (~550 nm). Attempts to shift the emission 
wavelength through derivatisation of luciferin have been 55 
successful in terms of wavelength shift (eg the 6’ amino 
derivatives  have produced red-shifts up to to 625 nm)10 but at the 
cost of light output, thus other ways to circumvent these 
limitations could be beneficial for some ATP assays.  
 Bioluminescence Resonance Energy transfer (BRET) is a 60 
natural phenomenon occurring in marine organisms such as 
Aequorea jellyfish and the sea pansy Renilla reniformis. It is a 
technique that has also been applied for noninvasive monitoring 
of BRET in live cells and whole-animal imaging11-13. Since the 
development of the first engineered BRET probe in 199814, it has 65 
been widely used in analytical biosensing and imaging 
particularly via conjugation of luciferase enzymes as donors and 
fluorescent proteins as acceptors15-18.  Despite red-emitting 
fluorescent proteins (RFPs) having the advantage of long 
wavelength emission, use of red-emitting fluorescent proteins as 70 
acceptors in the general development of BRET systems is not as 
advanced and diverse as the use of GFP variants. The main 
reasons are that fewer monomeric RFP variants were available, as 
well as the lower quantum yield and brightness of these 
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fluorescent proteins.  
 The most common application of BRET pairs introduced thus 
far has been in detection of protein-protein interactions 
(PPIs)11,13,15,19,20. Arai et al introduced the first red-emitting 
BRET system employed in a PPI, shortly after the discovery of 5 
RFPs. This used firefly luciferase as the donor and tetramer 
DsRFP as the acceptor21 (Quantum yield of DsRFP is 0.79). 
Among other successful luciferase-fluorescent protein fusion 
combinations that have been reported are Rluc-GFP 22, Rluc-
mOrange23, Fluc-mKate24, Fluc-mCherry25 and Rluc-EYFP13,26. 10 
Despite the reasonable performance of these BRET systems, most 
effort has been focused on their functionality as both an 
autofluorescent protein and a fluorescently tagged bioluminescent 
probe for in vivo imaging12,17,22, 23, 26. Noninvasive assesment PPIs 
in cell cultures or tissues has always been of special interest due 15 
to their core role in understanding diseases and providing 
theraputic targets.  
In analytical biosensing and imaging, bioluminescence 
and BRET have distinct advantages over fluorescence and Föster 
Resonance Energy Transfer (FRET). BRET does not require 20 
excitation of the donor by light, therefore shows significant lower 
background signal compared to FRET. Furthermore, the 
probability of undesirable direct excitation of the acceptor or 
photobleaching of the fluorophores, which are common 
drawbacks in FRET, are insignificant in BRET. In tissue imaging 25 
applications, BRET is thus more applicable than FRET for 
photoresponsive cells (e.g. retina cells and most plant tissues) or 
autofluorescent tissues (containing molecules such as NADH, 
collagen or flavins). Direct excitation in FRET can damage the 
tissue induced by a photogenerated chemical agent and adverse 30 
photochemical reactions. In addition, light sensitive pigments in 
photoresponsive tissues can react with specific wavelengths of 
light resulting in the activation of photosensitive biological 
processes.  
 Therefore, in a number of reports, BRET-based assays have 35 
been extended to study PPIs in living cells11,12,27,28. For example, 
Dragulescu-Andrasi et al have used BRET-based red-light 
emitting reporters to ratiometrically measured protein-protein 
interactions in deep-tissue small animal tumour models29. In 
another work, “BRET3”, a BRET-based probe composed of 40 
mOrange fluorescent protein (lEm 560 nm30) and a mutant Renilla 
luciferase (RLuc8) employs red emission to observe biological 
signals from live single cells as well as from superficial and deep-
tissue structures31. Recently a fusion protein of an enhanced YFP 
variant, Venus, and the RLuc8 was developed, which offers a 45 
BRET-based ratiometric Ca2+ indicator26. However, this 
luciferase enzyme does not use ATP as cofactor.  
On the other hand, fusion proteins of firefly luciferase with 
fluorescent proteins (Fluc-FP) do offer a dual colour protein with 
the potential for developing a useful ratiometric ATP 50 
measurement from the bioluminescence properties of luciferase 
and the fluorescence properties of fluorescent proteins. Such a 
dual signal measurement may be able to overcome issues of 
variability in signal intensity causing erroneous results. In another 
work, Branchini et al designed a sequential BRET-FRET system 55 
employing a firefly luciferase, red-emitting mKate fluorescent 
protein and nIR fluorescent dyes24. In this instance the ratiometric 
luminescent probe was used to assay protease activities.  
Here we examine a BRET-based technique for ATP 
measurement. A mutant firefly luciferase (x5) with higher pH- 60 
and thermostability than the wild-type luciferase (Fluc)32 was 
selected, coupled with mCherry30 as a BRET-based probe for 
ATP measurement. The combination of x5 Fluc with mCherry 
shifts some of the luminescent emission wavelength to the red, so 
that together with the greater pH- and thermostability for the x5 65 
firefly luciferase mutant, this could offer potential benefits either 
in the fusion protein format or the unfused protein, for BRET-
based ATP measurement techniques.   
Materials and Methods 
D-luciferin, ATP and EDTA, were purchased from Sigma-70 
Aldrich UK. Taq DNA polymerase and KOD Hot Start DNA 
Polymerase used for polymerase chain reaction (PCR), were 
purchased from Novagen. QuikChange II XL Site-Directed 
Mutagenesis Kit was purchased from Agilent Technologies and 
applied as per manufacturer’s protocol. Enzymes used for cloning 75 
(restriction enzymes, calf intestinal alkaline phosphatase, 
Antarctic phosphatase, T4 DNA ligase) and Quick Ligation kit 
were purchased from New England Biolabs and were used 
according to the manufacturer’s instructions. Plasmid pET16b 
(Novagen) containing x5 luciferase gene was a gift from Dr Erica 80 
Law, University of Cambridge. Plasmid pRSET B, containing the 
mCherry sequence, was kindly provided by Dr Allison Denis 
from Prof Gang Bao’s team at Georgia Tech University. 
Epicurian Coli® XL10-Gold ultracompetent cells were 
purchased from Stratagene and transformation was carried out as 85 
per manufacturer’s protocol. 
Construction of mCherry-Fluc fusion protein  
The pRSET B vector encoding x5-luc was used as a template for 
mCherry-Fluc fusion protein construction. The vector was 
subjected to site directed mutagenesis aimed to add two 90 
restriction sites of NdeI and BamHI for later insertion of the Fluc 
gene, while the stop codon was placed at the end of the sequence. 
The linker between mCherry and Fluc in the fusion protein 
consisted of the original seven aminoacid tail of mCherry, 
inserted by Shaner et al30 (plus one extra aminoacid of His), 95 
giving a linker sequence of: Gly, Met, Asp, Glu, Leu, Tyr, Lys, 
His. The resultant sequence was confirmed using the DNA 
Sequencing Facility, Department of Biochemistry, University of 
Cambridge. 
Expression and purification of His-tagged proteins 100 
Before expressing the protein, BL21(DE3) E. coli containing the 
desired plasmid were grown overnight in a starter culture of 15 
ml Luria Broth (LB). The culture was then transferred into 200 
ml fresh LB medium; grown to mid-log growth phase (OD600 = 
0.4 to 0.6) and induced with isopropyl β-D-thiogalactoside 105 
(IPTG). For expression of mCherry and x5-luc 1 mM IPTG were 
added at 25°C for 8 hrs. The fusion protein of mCherry-Fluc (CL) 
was expressed at 25°C with 0.1 mM IPTG resulting in the pure 
fusion protein of CL. Purity of proteins was analysed using 
SDS/PAGE (results not shown).  110 
Induced cells were collected by centrifugation (RC-5C centrifuge, 
Sorvall) at 9,500 rpm and 4°C for 10 min using the F10-6x500y 
rotor. The cell pellet was frozen and kept at -80ºC overnight. All 
processes of cell lysis and protein purification were carried out at 
4°C. Cell pellets were resuspended with 5 ml/g wet cells in the 115 
lysis buffer (10 mM phosphate buffer, pH 8.0, 2.7 mM KCl, 0.3 
M NaCl, 10 mM 2-mercaptoethanol, 20 % (v/v) glycerol, 1× 
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EDTA- free protease cocktail inhibitor with 2 % (v/v) Triton X-
100 and 20 mM imidazole) following by addition of 124 units/g 
wet cells benzonase® nuclease. Thawed resuspensions were 
mechanically pressed and put through three freeze – thaw cycles. 
All proteins were purified with the same technique previously 5 
described by Law et al32 using Ni-NTA agarose beads followed 
by PD-10 desalting columns. Protein concentrations were 
estimated with the Bradford method33 using the Coomassie Blue 
protein assay reagent kit from Pierce as per manufacturer’s 
protocol, with BSA as the standard.  10 
 
Fig.1	ATP measurement with BRET-based probes compared to x5 firefly 
luciferase. Luciferin concentration was 200 µM. Fluc concentration was 
fixed at 10 µM in all probes whilst the mCherry concentration was varied. 
(a) The concentrations used were: 10 µM x5 firefly luciferase, 10, 20 and 15 
30µM mCherry. The y-axis shows the total emission output at 30 ± 5 
seconds after ATP solution injection. Data were collected with a 
luminometer and correspond to relative total emission >270 nm. 
Bioluminescence measurements were carried out independently three 
times. (b) Constant concentration of Fluc (Luc) at 10 µM, with increasing 20 
concentration of mCherry (CH) from 5 to 30 µM. The spectra is 
normalised at the first peak around 550 nm. The graph shows the increase 
in BRET ratio with the increase in the acceptor (mCherry) concentration. 
ATP measurement 
Two probes were used to measure ATP based on BRET: (a) 25 
unfused mCherry and x5 Fluc in different concentration ratios of 
5:10, 10:10, 20:10 and 30:10 mCherry:Fluc (Fluc concentration 
was fixed at 10 µM), (b) pure mCherry-Fluc (CL) fusion protein 
expressed at 25°C. All probes were made in TEM buffer (0.1 M 
Tris/acetate, pH 7.8, 10 mM MgSO4 and 2 mM EDTA) 30 
containing 200 μM D-luciferin (D-LH2). A range of fresh ATP 
solutions (picomolar to millimolar concentrations) was prepared 
in UHP water. The data were read with both luminometer 
(Labsystems Luminoskan Ascent luminometer with Ascent 
software) which collects all emission above 270 nm and 35 
fluorometer (Cary-Eclipse fluorescence spectrophotometer 
(Varian)). The data were collected at 30 ± 5 seconds after the 
manual injection of ATP solution. 
BRET ratio calculation 
BRET ratio was measured with the fluorometer; the data were 40 
read at two peak-maxima wavelengths of typically 550 ± 5 nm 
and 615 ± 5 nm. The BRET ratio calculations were obtained by 
dividing the emission intensity at the secondary (mCherry) peak 
maximum (615 ± 5 nm) by emission intensity at the first (excited 
state of LH2 oxidation product) peak maximum (550 ± 5 nm).  45 
Results and Discussion 
ATP linked emission with BRET pairs 
Unfused mCherry and Fluc 
Figure 1a compares the luminescent intensity (all emission 
>270nm) for unfused BRET-probes of mCherry and Fluc in the 50 
presence of ATP and luciferin, for a constant concentration of 
Fluc; this shows a small decrease in overall light output with 
increase in mCherry concentration. This is connected with an 
emission profile that has shifted to longer wavelengths, consistent 
with resonant energy transfer to mCherry (fig. 1b), so that this 55 
reduction could be linked with the quantum yield for the 
fluorescent protein being <1 (QY for mCherry = 0.2230). For 
example, in this comparison, Fluc has a limit of detection of ~1 
pM ATP, but the lower total emission output with increase in 
resonance energy transfer to the fluorescent protein raises the 60 
detection limit so that for 30:10 µM mCherry:Fluc the limit has 
increased to 0.1 nM.  
 To explore whether the losses can be attributed entirely to the 
QY of the flurorescent protein (FP), the mCherry emission output 
can be predicted by considering the reduction in the fluorescence 65 
at the FP emission, due to the quantum yield of the fluorescent 
protein (QYFP), from the intensity of Fluc emission in the 
presence of FP (B) and the absence of FP (B0) at the same 
concentration, according to: 
       ………….(1) 70 
which allows the intensity of the fluorescent protein emission to 
be estimated according to: 
        ……………………..(2) 
Assuming a QY for mCherry of 0.22, Figure 2 demonstrates a 
remarkable fit between predicted and experimental data for the 75 
mCherry+Fluc combination (increasing mCherry Figure 2A).  
This also applies when the overall protein concentration is 
changed for a given mCherry:Fluc ratio (Figure 2B for 1:1 ratio), 
indicating that there are no ‘dark quenching’ reactions between 
the fluorescent protein and Fluc, reducing the total light output. 80 
This infers that the total luminescence and the BRET ratio 
(IFP/IFluc) are predictable, knowing the concentration and quantum 
yield of the acceptor, once the Stern-Volmer (KSVBL) constant for 
the BRET pair is known (figure 3C): 
  …………………(3).  85 
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Fig.2	Predicted	intensity	at	secondary	peak	(corresponding	to	mCherry	emission)	verses	the	experimental	data.	(a)	constant	concentration	of	Fluc	at	10	µM,	with	increasing	concentration	of	5 mCherry.	(b)	equimolar	mCherry+Fluc	from	2	to	12	µM,	.	This	suggests	that	the	fluorescence	emission	is	accurately	predictable	Shows	no	hidden	loss	of	energy	during	the	BRET	mechanism.	(c)	Relation	between	loss	in	total	emission	(compared	to	equimolar	Fluc),	BRET	ratio	and	percentage	shift	to	above	600	nm	in	1:1	10 combination	of	mCherry:Fluc	(fusion	protein	and	equimolar	unfused	proteins).	By	measuring	the	BRET	ratio,	the	loss	in	total	emission	and	the	light	shift	can	be	predicted	(see	text).	Black	circles	on	the	graph	represent	the	maximum	BRET	ratio	obtainable	by:	(1)	equimolar	mCherry+Fluc	(2)	CL	fusion	protein.		15 
ATP measurement via the BRET ratio  
It follows from the discussion above that trying to increase 
resonance energy transfer is thwarted by losses due to the QY of 
the fluorescent protein. Thus, a lower [FP] yields a higher light 
output and from the previous derivations, the ratio between the 20 
emission intensity due to donor and acceptor in the BRET pair is 
a function of ATP concentration, as can be seen visually in Figure 
3a. Thus, while the decrease in ATP concentration results in a 
decrease in the overall emission from the donor (Fluc-substrate 
complex) the BRET ratio increases (Fig. 3b) and the BRET ratio 25 
is a function of [acceptor]/[donor]. Depending on the acceptor 
concentration, lower detection is still limited by the QY for the 
acceptor. With this configuration, the BRET ratiometric 
measurement of ATP could be resolved down to 10-100 pM. 
Furthermore, for 10:10 - 10:25 mixtures, the slope of the BRET 30 
ratio calibration curve below 10-8M is independent of protein 
concentration, which makes it a robust method for ATP 
measurement. 
 
Fig.	3.	(a) A BRET probe consisting 10:10 µM [mCherry]:[Fluc] unfused 35 
proteins. Normalised intensity at the BRET emission wavelengths with 
ATP concentration . (b) The change in BRET ratios as a function of ATP 
concentration for unfused BRET pairs with different ratios of 
[mCherry]:[Fluc] with constant Fluc concentration at 10 µM and mCherry 
concentration from 5 to 30 µM. This is compared with the fused probe 40 
(CL) at 10 µM mCherry-Fluc fusion protein. The trend is constant in 
different probes and the data is independent of sensitivity (PMT) of 
fluorometer. 
 
 45 
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Fig.4	a) Relative	integrated	intensity	and	(b)	BRET	ratio	of	equimolar	concentrations	of	CL	fusion	protein	(10	µM),	in	comparison	with		unfused	equimolar	of	mCherry+Fluc	(10:10	µM)	are	shown.	5%	variations	between	experiments	(n=4).	Data	were	collected	with	5 fluorometer.	All	proteins	were	expressed	and	purified	under	the	same	conditions	as	the	fusion	proteins	(25°C,	8	hrs,	0.1	mM	IPTG).	Proteins	were	prepared	in	TEM	buffer.	The	substrate	consists	of	200	µM	D-luciferin,	1	mM	ATP	and	10	mM	MgSO4.	Data	were	at	30	±	5	seconds	after	substrate	injection.	10 
Fused mCherry-Fluc (CL) 
Based on this, it can be seen in Fig. 3b that a Fluc-mCherry 
fusion protein (CL) (with a forced intramolecular 1:1 ratio) 
follows a similar trend to the 10:10 mCherry:Fluc as would be 
expected, but the ratios are distinct from the unfused counterpart. 15 
A comparsion between the total emission (Fig. 4a) and the BRET 
ratio (Fig. 4b) of a fusion protein of mCherry-Fluc (CL) and 
equimolar mCherry+Fluc confirms this and reveals the probable 
contribution of inter- and intra-BRET in the FP-Fluc pair. 
Referring back to figure 2  (points 1 and 2) shows that the 20 
intensity of the emission above 600nm can still be predicted 
according to equation 2, depending on the QY of the acceptor. 
However, as seen in Fig. 4a, a CL fusion protein with a controlled 
1:1 ratio produces ~10% lower luminescence emission compared 
with the unfused proteins (Fig. 3b, 4b), but maintains the slope of 25 
the calibration curve as for the unfused proteins. To confirm this 
difference, a paired t-test was used (two-tailed, df=5). CL fusion 
protein compared to unfused proteins shows p-value of 1.2x10-5 
with mean of the difference=5.3x10-2, suggesting a significant 
difference between the BRET ratios with calculated p-values 30 
below 0.05 (95% confidence interval). This does not show 
whether this is just due to a change in the geometric terms in the 
Förster equation as a result of the fusion, in particular r6 
describing the inter-fluorophore distance or k, describing the 
dipole orientation, or some other change in Fluc kinetics. 35 
However, it does establish some vulnerability in an intensity 
based measurement for ATP. 
ATP measurement as a function of acceptor wavelength 
maximum 
It can be seen that at 10:10 µM Fluc:mCherry, ~28% of the light 40 
has been shifted above 600nm (Table 1), whereas a CL fusion 
protein achieves ~32% and 10:25µM Fluc:mCherry ~40% above 
600nm. This transfer of light above 600nm is a significant 
advantage. However, for measurements in tissues, with 
background autofluorescence below 600nm, the BRET ratio may 45 
still be compromised by needing the measurement of luciferase 
emission below 600nm against this background for the ratiometic 
measurement. However, for ATP concentrations above 10-11 M, 
there is a well resolved wavelenth maximum for the BRET 
emission above 600nm for all Fluc:mCherry or CL. This leads to 50 
another novel approach to a BRET measurement. 
 
Concentration 
(µM) 
Limit of ATP 
detection (M) by 
BRET ratio 
Relative 
light 
output (%) 
Photons above 
600 nm / total 
(%) 
10 Fluc 10-12 - 10-13 100 13 
10:5 µM 
Fluc:mCherry 
10-11 - 10-12 75±5 22±2 
10:10 µM 
Fluc:mCherry 
10-10 - 10-11 55±5 28±2 
10:20 µM 
Fluc:mCherry 
10-9 - 10-10 45±5 37±2 
10:30 µM 
Fluc:mCherry 
10-9 - 10-10 34±5 44±2 
10 µM CL 10-10 - 10-11 50±5 32±2 
Table	1	Comparison	of	light	emitted	above	600nm	for	different	Fluc:mCherry	combinations	and	CL	fusion	protein,	normalised	to	totallight	output	by	Fluc	at	the	same	concentration	of	10µM.	55 
The idea that the fusion protein geometry highlights the energy 
transfer due to dipole or distance, leads to examination of the 
mechanism of the bioluminescence. Excitation to the 
oxyluciferin* state causes an increase in the dipole moment and 
reverses its direction34,35 leading to disruption of bonds between 60 
oxyluciferin* and the enzyme binding site with partial 
dissociation of the enzyme-oxyluciferin* complex. Emission and 
deactivation can occur from either the associated or dissociated 
oxyluciferin*36,37. The kinetics of this reorganisation causes 
conformational changes in the oxyluciferin* (including keto-enol 65 
tautomerism, scheme 1), which may result in a green or red shift 
in the fluorescent emission, imposed by interaction with the 
active site, which determines the final emission wavelength and 
peak broadening for a particular luciferase.  
 70 
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Scheme	1	BRET in Luciferase-Luciferin reaction: Luciferase acts as enzyme and donor, while mCherry is 
the acceptor. ATP measurement via the luciferase-luciferin signal (on the left) and the BRET pair signal due to the 
luciferase-luciferin donor and mCherry acceptor (on the right). Conformational changes in the oxyluciferin* (including 5 
keto-enol tautomerism), results in a green or red shift in the fluorescent emission 
 
 
 Rebartz et al38 has disentangled the keto–enol tautomerism for 
oxyluciferin to identify the individual spectral contributors. This 10 
works suggests that the spectra range from the phenol-enol at low 
wavelengths through phenol-keto < phenolate-enol < 
phenolenolate < phenolate-enolate to phenolate-keto at highest 
wavelength. These equilibria are dependent on protonation, 
which in luciferase is served through the amino acid interactions 15 
in the active site. Since luciferase-bound luciferyl adenylate is 
one of the first intermediates in the mechanistic pathway, it might 
be postulated that at low ATP concentration, the conformational 
reorganization which results in changes in this equilibrium would 
result in an ATP dependent product, and that the tautomer and its 20 
level of protonation could be revealed through measurement of 
the absorption spectra and possibly also the emission wavelength 
of the excited state oxyluciferin product. 
The small blue shift in donor (Fluc) wavelength seen here, with 
increase in ATP concentration is consistent with such a change in 25 
the keto-enol ratio due to the reorganisation of the oxyluciferin*, 
influenced by the concentration of ATP. However, the shift is 
small and not adequate to be correlated directly with [ATP]. 
On the other hand, the increase in ATP concentration is also 
accompanied by a red-shift in the acceptor peak corresponding to 30 
mCherry fluorescence emission (Figure 5a). This is a much larger 
shift, which can be correlated to [ATP]. mCherry has an emission 
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maximum of 611-613nm when excited at 587nm39, but as can be 
seen in figure 5b, the mCherry emission spectrum is dependent 
on excitation wavelength. At 10µM mCherry has a maximum 
emission <614nm when excited around 580nm (figure 5b), but 
reached a maximum 621±1nm when excited in UV Range (<300 5 
nm). So, we can correlate the shift in acceptor emission 
wavelength to a shift in excitation (donor) wavelength due to an 
ATP-dependent change in the oxyluciferin* reorganisation.  
 
Fig.5		(a)	The change in the wavelength of mCherry fluorescence 10 
maximum emission in a BRET pair of 10:10 µM [mCherry]:[Fluc] and 
CL fusion protein. The graph shows a blue-shift in the maximum 
emission wavelength with an in increase in ATP concentration (donor 
emission) with constant acceptor concentration (Error: ±1 nm). (b) 
mCherry (10 µM) excited at different wavelengths. mCherry emission 15 
excited at UV range appears at longer wavelengths than excitation in 
visible range. 	
 This leads to a robust ATP dependent calibration: like the 
BRET ratio measurement, the slope of the calibration curve for 
mCherry lmax vs ATP  is independent of fused or unfused protein 20 
in the range 10-11 - 10-5M ATP and has a ‘baseline’ calibration 
independent of concentration above 10-4M (figure 5a). This 
produces a calibration of: 𝜆!"# − 𝜆[%&'])*+!", = 𝑥 [ATP]=10-(/0+.2/3)	M 25 
Importantly, this is the first ATP dependent measurement of 
BRET that can be performed exclusively above 600nm. 
Conclusion  
A BRET-based measurement of ATP suggests some potential 
advantages over a conventional method employing pure Fluc. 30 
Emission above 600nm becomes possible rather than the 
conventional pure firefly luciferase in which the emitted green 
light is largely absorbed by the tissue. By employing fused or 
unfused mCherry and Fluc, the BRET structure can transfer more 
than 45% of the output light to wavelengths above 600 nm 35 
dependent on [ATP]. However, on the down side, since the 
quantum yield for mCherry is only 0.2230, the BRET mechanism 
results in a significant overall intensity loss. Improved BRET 
efficiency with recently reported red-emitting fluorescent proteins 
such as mKate240 could be a good alternative due to its high 40 
brightness (0.4 compared to 0.22 of mCherry), or eqFP650 can be 
used for a more red-shifted emission (Em max at 635 nm)41, so 
that the BRET method does have a greater potential than 
achieved with this BRET pair. 
Additionally, ratiometric measurement of the BRET donor and 45 
acceptor, as proposed here, provides a method that is independent 
of protein concentration within a broad range and resiliant to any 
protein loss with time. There is a higher energy transfer for the 
fusion protein of CL, probably associated with transfer distance 
and dipole orientation and is attractive for in vivo measurement 50 
of ATP, where position of the members of a BRET pair may be 
difficult to manage otherwise. 
Despite the advantages, a main drawback is the ongoing need to 
obtain a measurement at the lower Fluc wavelength as well as the 
longer wavelength FP, so that a novel alternative approach that 55 
avoids intensity measurements, relating ATP concentration to the 
red shift in the mCherry emission wavelength, provides an 
interesting alternative for ATP measurement. We propose that the 
BRET pair allows fast energy transfer from an unstable high 
energy green shifted conformer of the ATP-oxyluciferin*-enzyme 60 
complex, before its rearrangement.  The result is that the BRET is 
dominated by this transfer at low [ATP] (below KM), but at 
higher concentrations RET originates from the Fluc emission 
>540nm. Since excitation wavelength dependent emission is also 
a feature seen in other FPs, there is potential for transfer to other 65 
FPs and better  lmax resolution at lower concentrations with the 
brighter FPs like mKate2. 
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